Novartis (NVS) to Release Earnings on Tuesday

Novartis (NYSE:NVS) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of $1.91 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Novartis Price Performance

Novartis stock opened at $113.79 on Monday. The company has a market capitalization of $232.59 billion, a PE ratio of 15.36, a P/E/G ratio of 1.66 and a beta of 0.57. The company has a current ratio of 0.93, a quick ratio of 0.72 and a debt-to-equity ratio of 0.47. The stock has a 50-day moving average price of $116.42 and a two-hundred day moving average price of $108.64. Novartis has a 12 month low of $92.19 and a 12 month high of $120.92.

Wall Street Analysts Forecast Growth

NVS has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Novartis in a research report on Friday, July 19th. Bank of America lowered shares of Novartis from a “buy” rating to a “neutral” rating and cut their price target for the stock from $135.00 to $130.00 in a report on Wednesday, September 11th. Jefferies Financial Group downgraded Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 3rd. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $121.00 price target (up previously from $119.00) on shares of Novartis in a research report on Thursday, September 5th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Novartis has an average rating of “Hold” and a consensus target price of $120.70.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.